There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
Tag Archives: Company
Only 51 authorized licenses have been given to suppliers of medical marijuana in Canada. Canopy Growth Corporation holds four of them.
On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.
The results for Canopy Growth’s stock have been terrific so far, yielding a return of over 152% since inception. The stock has been performing well despite lacklustre results and frequent losses.
Organa Brands is setting itself up to be the best and biggest nation-wide cannabis company. This multi-brand company posts top line sales of over $100 million.
The Auscann Group Holdings Ltd share price has continued its strong run and is up a further 6% to 46 cents today. Why has it jumped? Let’s look to find out.
MedReleaf is one of less than four dozen licensed producers and retailers of medical cannabis products in Canada. The company was founded just four years ago, and it focuses on supplying dried cannabis, cannabis oils, and cannabis oil capsules to qualified medical patients in Canada.
If these headsets make ordering marijuana easier, which would in turn increase sales, this technology will be another boon for marijuana dispensary stocks.
Aurora Cannabis Inc. today is one of the pre-eminent marijuana producers listed on the TSX Venture Exchange with a market capitalization just shy of $750 million, making it the fourth-largest marijuana stock behind only GW Pharmaceuticals PLC- ADR, Canopy Growth Corp., and Aphria Inc.
Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Warren Buffett is well known as the most successful investor of all time. Buffett spent his formative years under the tutelage of Benjamin Graham, who is known today as the “father of value investing.” Let’s see whether or not Aphria Inc. can pass Buffett’s mentor’s criteriea test.
As California’s medical marijuana industry has grown to an $800 million dollar business, one company is hoping to take advantage of that by delivery the product directly to the customer.
Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
Though there are a number of direct players in the industry, some of the most surprising growth can be seen in emerging industry players. One such name is Scotts Miracle-Gro.
On July 1, 2017, Nevada will legalize the use and sale of recreational marijuana, which could be a catalyst for long-term gains for three cannabis stocks.
The industry and the Canopy Growth Corp. were going to be the next big thing for investors, but things have cooled down gradually over the past few months.
Here is a novel concept could increase the safety of cannabis deliveries and be a boon for marijuana stocks: drone deliveries. Not only will drone deliveries increase safety, but they will also make delivery faster and more convenient.
MedReleaf Corp. is the latest cannabis stock to hit the TSX. Could they be the spark to reignite the second wave of the green rush?
Multi-state cannabis company iAnthus Capital Management has now planted its flag in New York with Monday’s announced acquisition of Valley Agriceuticals.
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Oh, how the mighty have fallen. Shares of Canopy Growth Corp. have dropped by over $6 a share, or 47.5%, since the middle of February.
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?
How about another cannabis company to spark up your interest? Newstrike Ltd. is Canada’s newest pot stock that will be hitting the TSX Venture Exchange this Thursday.
Canadian band, the Tragically Hip are hoping to get ahead by a few days, partnering with a Canadian medical marijuana company just before it’s set to go public.
Aurora Cannabis Inc. has been a favourite marijuana stock for some time. Should you be watching closely for an opportunity to buy the dip?
The recently debuted marijuana stock ETF, the Horizons Medical Marijuana Life Sciences ETF, has lost value for those who’ve decided to take the plunge.
The Scotts Miracle-Gro Company has positioned itself to benefit from the rising support for marijuana without directly cultivating the plant itself, so as to avoid any legal repercussions.
Los Angeles’ Marijuana Don of Hollywood, BigMike Straumietis, shatters the stoner stereotype with his multi-million dollar cannabis company.
Here’s a pot stock that should prove immune to the adverse political winds emanating from the nation’s capital as marijuana is transitioning in the public eye.
Watch Bradley Orr, CEO of Stratos, and Michael Katz, CEO of Evoxe, talk about processing and manufacturing cannabis at the World of Cannabis in Las Vegas.
You definitely don’t want to bet the family farm on such a speculative investment like Aurora Cannabis Inc., but there’s a substantial amount of upside if you don’t mind the large amount of risk.
After an Ottawa ban on celebrity endorsements of marijuana products, Snoop Dogg will not be able to explicitly promote Canopy’s Tweed-branded products.
In this World of Cannabis Interview, watch Caroline Cahill, Managing Editor of http://www.MJINews.com and Marijuana Industry News magazine, interview Bradley Orr, CEO of Stratos.
Aphria Inc (TSE:APH) is now the front-runner in the race to hit the billion-dollar valuation mark.
In this World of Cannabis Interview, watch Caroline Cahill, Managing Editor of MJINews.com, interview Jarrod Smith, CEO of Rolling Paper Depot.
In this World of Cannabis Interview, watch Caroline Cahill, Managing Editor of MJINews.com and Marijuana Industry News magazine, interview Eric Lachange, COO of Pathogen DX.
As Canada heads toward legalization of marijuana, Alberta producer Aurora Cannabis is focused on expansion with ambitions to raise a $160-million “war chest” from investors who are anxious to profit from what is expected to be a multibillion industry.
A west New York-based biotech company has successfully grown a strain of marijuana that contains zero THC, a feat the company says will transform the medical marijuana industry.
In this World of Cannabis Interview, watch Caroline Cahill, Managing Editor of MJINews.com and Marijuana Industry News magazine, interview Kevin Sutherland, CEO of Canna Mergers.
Are you concerned about the pedigree of cannabis investment management? If so, just take a good look at the management at MJIC. MJIC is a holding company deploying a diversified business plan in the legal cannabis industry.
Insys Therapeutics’ stock rose on good news — but not tremendously so.
In this World of Cannabis interview, watch Caroline Cahill, Managing Editor of Marijuana Industry News, interview Ryan Brown, Co-founder of Tetra Bio Pharma.
There are a number of big institutions, including mutual funds, pension funds, and investment banks, that use the TSX Composite and its sub-indices as performance benchmarks for their portfolios. The addition of Canopy to the index will introduce some new dimensions to the index’s performance.
Maryland’s medical cannabis program is expected to be fully up and running later this year, and in the coming months, patients can register with the state. But there’s a series of issues that still need to be resolved, even as marijuana growers and dispensaries are getting ready to open for business.
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.
Investors are becoming more and more impressed with the job CEO Terry Booth and his team are doing at Aurora Cannabis Inc. After posting strong Q2 results and closing a C$75 million financing, there’s a lot to like with company.
Investors in cannabis companies had an eventful 2016 with the approval of recreational marijuana usage in the states of California, Massachusetts, Maine, and Nevada providing a boost to all sorts of marijuana stocks. Of particular note, shares of Corbus Pharmaceuticals (NASDAQ: CRBP) posted a whopping 600% gain in 2016 following positive phase 2 data.
Canopy Growth Corp. has garnered the most attention and established itself as the market leader; however, there is another company in the Canadian marijuana industry that could emerge as a potential winner.
As of Wednesday, traders on the Toronto Stock Exchange can buy and sell “WEED.”